Featured Articles

Features
Computerized system validation (CSV) remains a cornerstone of regulatory compliance, but it is still time-consuming, resource-intensive, and prone to human error. Risk assessments, test development, traceability, and documentation absorb enormous effort and often slow down innovation. Artificial intelligence (AI) has the potential to change this.
Features

Categorization offers a useful starting point for assessing the risk of failure for individual software components, but it is not a validation checklist. Organizations must apply critical thinking to combine categorization with risk assessment and supplier assessments to appropriately scale life cycle activities and manage risk.

Features
Large language models (LLMs) can enable decision support in pharmaceutical manufacturing but can also create risks through overreliance. LLM-enabled computerized systems have the potential to increase assessment consistency and performance in a scalable way for automated decision-making workflows.
Features

This article presents a model for promoting data quality of real-world data and evidence (RWD/RWE) and GxP processes with references to ISO 8000 for data quality management, making it a common language between regulated and nonregulated organizations.

Features

Data integrity drives quality and compliance. Content addressable storage (CAS) stores and retrieves files by content type—not file location—using cryptographic fingerprints. The result: a mathematically provable version control, without broken links and far fewer audit headaches.

Features
Clinical trial sponsors who delegate responsibilities to service providers supporting anything from a small, single-site Phase I study to a global Phase III program are now operating under a fully revised ICH GCP E6(R3).
Technical

A single global digital chemistry, manufacturing, and controls (CMC) dossier is rapidly transitioning from a bold vision to a practical reality. However, realizing the full potential of these innovations requires significant coordination to harmonize and align across initiatives.

Technical

To accelerate the adoption of innovation in the global administration of the pharmaceutical industry, regulatory authorities and industry trade organizations must expand their scope and pursue a collaborative approach to recognition and reliance to streamline processes, enhance product quality, and improve patient access to medicines.

InTouch

Thanabalan “Thana” Subramanian is Head of the Digital Quality team in the quality, regulatory, digital consultancy firm Product Life Group. He is responsible for a team of 20 consultants and supports the Digital Quality Center of Excellence, covering IT compliance, computer software validation (CSV), data integrity, CSV auditing, and CSV training. Before joining Integrity, he worked for...

InTouch

Frank Henrichmann is an expert in quality management, computerized system validation, and compliance, especially in clinical trials and pharmacovigilance. With over 25 years of experience in quality functions within the pharmaceutical industry, he has gained deep expertise in implementing and validating computerized systems within GxP-regulated environments, having worked with organizations...

InTouch

The 2025 ISPE D/A/CH workshop on “Pharma’s Journey to Digital Manufacturing and Supply” united pharma leaders, technology experts, and regulatory authorities for three days of intense exchange on the digital transformation of our industry.

Features
Pharmaceuticals are not only regulated by traditional pharmaceutical legislation but are also increasingly influenced by related environmental and stewardship laws. Extended producer responsibility (EPR) is reshaping the pharmaceutical industry with regulatory burdens, challenges, and strategic opportunities.
Features

Sustainability principles can be effectively integrated into commissioning and qualification (C&Q) projects to support environmental goals without compromising compliance, quality, or patient safety. By positioning C&Q as both a verification tool and an enabler of sustainable intent, this article outlines a practical path for the pharmaceutical sector to enhance operational efficiency,...

Features

The development of platform drug delivery devices for combination products offers a transformative approach to drug delivery by enabling the reuse of device data across multiple drug and device combinations.

Online Exclusives
Over the past decade, Advanced Therapy Medicinal Products (ATMPs) have introduced a significant shift to pharmaceutical manufacturing, introducing a new generation of personalized medicines that demonstrate promising results for diseases with few or no treatment options. In the United States, approximately 34,000 patients have received CAR T-cell therapies since 2024. With 17 authorized products...
Features

Advancements in technology—such as process intensification, continuous manufacturing, and 3D printing—are enabling transportable and point-of-care (PoC) medicines manufacturing, especially with the rise of personalized medicine. Modular, small-scale production systems are particularly well-suited for cell and gene therapies and other advanced therapy medicinal products (ATMPs) designed for...

Features

Simplified approaches that enable changes to analytical procedures over their lifecycle are needed to allow continual improvements and adaptations due to technological obsolescence and other challenges. This article reflects on the positive impact that the recent ICH Q14 guidance can have on facilitating these changes. Five examples are provided that are based on scenarios in which analytical...

Features

The International Council for Harmonisation (ICH) Q2(R2) and Q14 guidelines, finalized in late 2023, outline strategies for analytical procedure development, validation, and lifecycle management. As global implementation progresses, ISPE’s PQLI® Analytical Method Strategy Team surveyed industry stakeholders in mid-2024 to assess readiness, identify opportunities, and highlight areas...

Features

In April 2023, ISPE launched a survey to understand the sources of barriers to technological innovation within the pharmaceutical industry. This survey is part of an expansive and significant initiative by ISPE, Enabling Global Pharma Innovation: Delivering for Patients, which aims to promote consistent and harmonized interpretation and implementation of guidelines issued by the International...

Features

Defining requirements for calibration and routine testing of weighing equipment in the laboratory and production remains a complex endeavor for pharmaceutical companies. Applying sound, risk-based metrological strategies across the entire pharmaceutical value chain will help manufacturers ensure compliance, consumer safety, and commercial success.

Features

The United States Pharmacopeia (USP) Packaging and Distribution Expert Committee approved chapters 665 and 1665 in 2024. These chapters establish clear and general guidelines for the use of plastic materials in process equipment used within the pharmaceutical and biotechnology industries. Their publication has raised new questions regarding the role of polymeric materials in manufacturing...

Features

The increasing digitalization of the pharmaceutical and medical device industry has created novel cybersecurity challenges, particularly with the rapid advancement of artificial intelligence (AI) technologies. This article examines the dual nature of AI as both a potential threat vector and a powerful defensive tool.

Features

The move to digital transformation represents a true paradigm shift in manufacturing, enabling organizations to leverage advanced technologies such as the Industrial Internet of Things (IIoT), cloud computing, and artificial intelligence (AI) to ensure compliance and secure a competitive advantage. This article presents a working definition of digital transformation, the components involved in...

Explore

White Paper
This whitepaper provides principles and practical expectations for manufacturing operations within the scope of GMP Annex 1, focusing on four areas: environmental monitoring and control; aseptic process validation; equipment and facility design; and personnel practices. Each subject area was drafted as an individual chapter to the whitepaper by multicompany and multidisciplinary teams with...
White Paper
The life science validation sector is evolving with a focus on risk-based methodologies and increased access to digital data, driving innovation. The rise of Digital Validation Tools (DVTs) reflects the industry's emphasis on data integrity and principles of Pharma 4.0 and Validation 4.0. These advancements streamline monitoring and provide real-time insights into validated statuses through...
White Paper

Currently, there is no single guidance document providing a comprehensive roadmap for executing digital validation. While elements from ISPE GAMP® Guides Series and the ISPE Baseline® Guide: Volume 8 – Pharma 4.0™, apply to digital validation, there is no consolidated resource addressing common questions. The authors of this Concept Paper therefore advocate for the development of a Good...

Latest Articles

iSpeak Blog

Life science facilities are increasingly expanding their laboratory footprints to bring processes in-house, consolidate testing, and optimize underutilized office space. In today’s dynamic business environment, where agility, speed, and cost efficiency are paramount, converting office areas to laboratory space has become a strategic way to streamline operations while maintaining flexibility...

iSpeak Blog

Digital transformation in the pharmaceutical industry is no longer a strategic ambition—it is an operational reality. Artificial intelligence (AI), cloud platforms, and data-driven automation are increasingly embedded in GxP-critical processes, from development and manufacturing to quality assurance and supply chain operations. While technology evolves rapidly, regulatory expectations around...

iSpeak Blog

In the fast-paced world of life sciences, the ability to connect with global experts, solve technical hurdles in real-time, and stay ahead of regulatory shifts is not just a benefit—it is a professional necessity. For years, ISPE Engage has served as the premier digital home for the global ISPE community, acting as the connective tissue between thousands of professionals, regulators, and...

iSpeak Blog
The movement toward ready-to-use (RTU) and ready-to-fill (RTF) primary packaging has reached a pivotal moment. Regulators are tightening expectations, supply chains are stressed, and manufacturers are balancing cost with contamination control. The Component Quality track at the 2026 ISPE Aseptic Conference gathers three practice-focused presentations that together provide evidence, methods, and...
iSpeak Blog

EU GMP Annex 1 has pushed sterile manufacturing conversations from “what does it mean?” to “how is it proven?”  Annex 1 requires a facility-wide, integrated contamination control strategy (CCS) that defines critical control points, verifies the effectiveness of design and operational controls, and is actively reviewed to drive continual improvement. 

iSpeak Blog
The authors have explored how a shift in organizational culture can transform AI from a mere technical tool into a true collaborative partner, enhancing human expertise and driving innovation. The authors have also shared how AI is revolutionizing quality assurance throughout the pharmaceutical manufacturing lifecycle, from raw material intake to predictive maintenance, delivering greater...
iSpeak Blog
In the last ISPE article developed by this author, titled “Concluding Compliance Challenges with Validation 4.0”, seven pillars of Validation 4.0 were identified as necessary to support the key themes of Pharma 4.0™ operating model. The article concluded with a caveat that only the final publication of CSA guidance will provide a definitive answer to this conundrum. Now with the publication of...
iSpeak Blog

The revised EU GMP Annex 1 has placed renewed emphasis on developing a holistic approach to contamination control: leveraging barrier technologies, automation, rapid microbial methods and proactive management of airflow patterns, compelling manufacturers to rethink how aseptic systems are designed, qualified, and operated. With these evolving regulatory expectations and growing complexity in...

iSpeak Blog
Facilities of the future entails embracing an end-to-end vision of how design, digital strategy, manufacturing, and quality work together to drive innovation and deliver medicines to patients. This shift reflects a more complete, more mature understanding of what it takes to build facilities that can support today’s science and tomorrow’s breakthroughs.
iSpeak Blog
Building on the discussion in Part One about the need for standardization across research and development (R&D) and quality control (QC) laboratories, this second part of the series explores how laboratories can progress toward plug-and-play automation.
iSpeak Blog

Pharma companies are currently experiencing unprecedented challenges as a result of external factors such as geopolitics, the adoption of new modalities, rapidly changing technologies including digital ones, and also regulatory changes. In order to overcome these challenges, the pharmaceutical industry must accelerate and embrace new technologies, approaches and thinking. Hence to grow and...

iSpeak Blog

The 2025 ISPE International Honor Awards were held during the Membership Meeting and Awards Lunch during the 2025 ISPE Annual Meeting & Expo in Charlotte, North Carolina, USA. The ceremony recognized ISPE members and contributors whose dedication and service exemplify what it means to Shape the Future of Pharma™. The Emerging Leader Member of the Year Award was presented to Ryan Mazur and...

iSpeak Blog
Explore three insightful sessions on the future of pharmaceutical facilities from thought leaders who presented at the 2025 Facilities of the Future Conference: “A New Standard for Designing Agile Manufacturing Facilities,” “Executive Forum Dinner and Panel Discussion,” and “Lilly’s Manufacturing Innovation to Reach More Patients.” These videos feature expert perspectives on flexible design, the...
iSpeak Blog

The evolution of pharmaceutical manufacturing has progressed through several stages—from manual drug compounding to fully automated lines with rigorous quality control. Today, a new era—Pharma 4.0™—is unfolding, offering both transformative opportunities and complex challenges driven by market needs, regulatory requirements, and rapid digital innovation.

Current Issue

January / February 2026

As the pharmaceutical landscape continues to evolve, this issue highlights use of AI and GAMP ® frameworks for different areas of the industry including quality and data management.